Association Between Symptom Improvement and Change of Body Mass Index, Lipid Profile, and Leptin, Ghrelin, and Cholecystokinin Levels During 6-Week Olanzapine Treatment in Patients With First-Episode Psychosis

2010 ◽  
Vol 30 (5) ◽  
pp. 636-638 ◽  
Author(s):  
Cengiz Basoglu ◽  
Ozgur Oner ◽  
Alpay M. Ates ◽  
Ayhan Algul ◽  
Umit Basar Semiz ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Lipid Profile ◽  
Body Mass ◽  
First Episode Psychosis ◽  
First Episode ◽  
Symptom Improvement ◽  
Olanzapine Treatment ◽  
Episode Psychosis

scholarly journals Weight Gain in First-Episode Psychosis

2003 ◽  
Vol 48 (4) ◽  
pp. 272-276 ◽  
Author(s):  
Jean Addington ◽  
Chrystal Mansley ◽  
Donald Addington
Keyword(s):  
Body Mass Index ◽  
Weight Gain ◽  
Body Mass ◽  
First Episode Psychosis ◽  
First Episode ◽  
First Year ◽  
Optimum Treatment ◽  
Episode Psychosis ◽  
Second Generation Antipsychotics ◽  
Potential Weight

Objective: To examine the extent of weight gain in the first year of treatment in an early psychosis program. Method: Subjects were 114 individuals who had experienced a first episode of psychosis and had completed 1 year in a comprehensive first-episode program. Weight and body mass index were calculated on entry to the program and at 6 and 12 months. Most of the subjects were all being prescribed second-generation antipsychotics. Results: Significant increases in mean weight were observed in these young individuals over the course of the first year of treatment. Conclusions: If we are to work toward optimum treatment for first-episode subjects then potential weight gain needs to be addressed at the beginning of treatment and monitored during treatment.

scholarly journals Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients

2012 ◽  
Vol 42 (9) ◽  
pp. 1893-1901 ◽  
Author(s):  
N. Hepgul ◽  
C. M. Pariante ◽  
S. Dipasquale ◽  
M. DiForti ◽  
H. Taylor ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Childhood Maltreatment ◽  
First Episode Psychosis ◽  
First Episode ◽  
Healthy Controls ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
The Metabolic Syndrome ◽  
Episode Psychosis

BackgroundThe high incidence of the metabolic syndrome in patients with psychosis is mainly attributed to antipsychotic treatment. However, it is also possible that psychological stress plays a role, inducing a chronic inflammatory process that may predispose to the development of metabolic abnormalities. We investigated the association between childhood maltreatment and inflammatory and metabolic biomarkers in subjects with first-episode psychosis and healthy controls.MethodBody mass index (BMI), weight and waist circumference were measured in 95 first-episode psychosis patients and 97 healthy controls. Inflammatory and metabolic markers were measured in a subsample of 28 patients and 45 controls. In all the subjects we collected information on childhood maltreatment and recent stressors.ResultsPatients with childhood maltreatment had higher BMI [25.0 (s.e.=0.6) kg/m2] and C-reactive protein (CRP) levels [1.1 (s.e.=0.6) mg/dl] when compared with healthy controls [23.4 (s.e.=0.4) kg/m2, p=0.030 and 0.2 (s.e.=0.1) mg/dl, p=0.009, respectively]. In contrast, patients without childhood maltreatment were not significantly different from healthy controls for either BMI [24.7 (s.e.=0.6) kg/m2, p=0.07] or CRP levels [0.5 (s.e.=0.2) mg/dl, p=0.25]. After controlling for the effect of BMI, the difference in CRP levels across the three groups remained significant (F2,58=3.6, p=0.035), suggesting that the increase in inflammation was not driven by an increase in adipose tissue.ConclusionsChildhood maltreatment is associated with higher BMI, and increased CRP levels, in patients with a first-episode psychosis. Further studies need to confirm the mechanisms underlying the putative causal relationship between childhood maltreatment and higher BMI, and whether this is indeed mediated by increased inflammation.

scholarly journals Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

2005 ◽  
Vol 187 (6) ◽  
pp. 537-543 ◽  
Author(s):  
Robert B. Zipursky ◽  
Hongbin Gu ◽  
Alan I. Green ◽  
Diana O. Perkins ◽  
Mauricio F. Tohen ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Weight Gain ◽  
Time Course ◽  
Atypical Antipsychotics ◽  
First Episode Psychosis ◽  
First Episode ◽  
Episode Psychosis ◽  
Study Completion ◽  
Clinically Significant ◽  
Potentially Clinically Significant

BackgroundSubstantial weight gain is common with many atypical antipsychotics.AimsTo evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol.MethodSurvival analysis assessed time to potentially clinically significant weight gain (⩾7%) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches.ResultsAfter 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001).ConclusionsOlanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.

scholarly journals Sex-Specific Effect of Serum Lipids and Body Mass Index on Psychotic Symptoms, a Cross-Sectional Study of First-Episode Psychosis Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Priyanthi B. Gjerde ◽  
Carmen E. Simonsen ◽  
Trine V. Lagerberg ◽  
Nils Eiel Steen ◽  
Ole A. Andreassen ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Serum Lipid ◽  
Serum Lipids ◽  
Negative Symptoms ◽  
First Episode Psychosis ◽  
First Episode ◽  
Lipid Levels ◽  
Cross Sectional ◽  
Episode Psychosis ◽  
The Relationship

Background: Schizophrenia is a disorder with considerable heterogeneity in course and outcomes, which is in part related to the patients' sex. Studies report a link between serum lipids, body mass index (BMI), and therapeutic response. However, the role of sex in these relationships is poorly understood. In a cross-sectional sample of first-episode psychosis (FEP) patients, we investigated if the relationship between serum lipid levels (total cholesterol, HDL-C, LDL-C, and triglycerides), BMI, and symptoms differs between the sexes.Methods: We included 435 FEP patients (males: N = 283, 65%) from the ongoing Thematically Organized Psychosis (TOP) study. Data on clinical status, antipsychotics, lifestyle, serum lipid levels, and BMI were obtained. The Positive and Negative Syndrome Scale (PANSS) and the Calgary Depression Scale for Schizophrenia (CDSS) were used to assess psychotic and depressive symptoms. General linear models were employed to examine the relationship between metabolic variables and symptomatology.Results: We observed a female-specific association between serum HDL-C levels and negative symptoms (B = −2.24, p = 0.03) and between triglycerides levels (B = 1.48, p = 0.04) and BMI (B = 0.27, p = 0.001) with depressive symptoms. When controlling for BMI, only the association between serum HDL-C levels and negative symptoms remained significant. Moreover, the HDL-C and BMI associations remained significant after controlling for demography, lifestyle, and illness-related factors.Conclusion: We found a relationship between metabolic factors and psychiatric symptoms in FEP patients that was sex-dependent.

Sign in / Sign up

Export Citation Format

Share Document